Download PDF
CC BY 4.0 · Indian J Med Paediatr Oncol 2024; 45(02): 157-162
DOI: 10.1055/s-0042-1748797
Images in Oncology

PD-L1 Testing and Assessment: Practical Considerations for Oncologist and Pathologist

Sunil Pasricha
1   Department of Pathology, Rajiv Gandhi Cancer Institute & Research Centre, Delhi, India
,
Garima Durga 
1   Department of Pathology, Rajiv Gandhi Cancer Institute & Research Centre, Delhi, India
,
Venkata Pradeep Babu Koyyala 
2   Department of Medical Oncology, Tezpur cancer center, Assam cancer care foundation, Assam, India
,
Ankush Jajodia 
3   3Department of Radiology, Juravinski hospital, McMaster university, Canada
,
Gurudutt Gupta
1   Department of Pathology, Rajiv Gandhi Cancer Institute & Research Centre, Delhi, India
,
Anurag Mehta
4   Lab Services & Research, Rajiv Gandhi Cancer Institute & Research Centre, Delhi, India
› Author Affiliations
› Further Information
   Permissions and Reprints

Introduction

Recently, immunotherapy with anti-PD-1(programmed cell death protein 1) or anti-PD-L1 (programmed cell death ligand 1) antibodies has shown both favorable and durable responses in a subset of patients with metastatic and advanced cancers. Although no robust predictive biomarker for immune checkpoint inhibitors (ICI) has been established till date, PD-L1 immunohistochemistry (IHC) testing has emerged with a passable utility. However, PD-L1 is still far from being a perfect biomarker. Nevertheless, PD-L1 testing by IHC to evaluate the immunoexpression of PD-L1 protein in tumor cells and/or immune cells is a useful predictive biomarker for predicting response to ICI.[1] [2] [3] [4]

Source of Support

None declared.




Publication History

Article published online:
28 November 2022

© 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Lantuejoul S, Sound-Tsao M, Cooper WA. et al. PD-L1 testing for lung cancer in 2019: perspective from the IASLC pathology committee. J Thorac Oncol 2020; 15 (04) 499-519
    CrossrefPubMedGoogle Scholar
  • 2 Ionescu DN, Downes MR, Christofides A, Tsao MS. Harmonization of PD-L1 testing in oncology: a Canadian pathology perspective. Curr Oncol 2018; 25 (03) e209-e216
    CrossrefPubMedGoogle Scholar
  • 3 Davis AA, Patel VG. The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors. J Immunotherapy Cancer 2019; 278 (07) DOI: 10.1186/s40425-019-0768-9.
    CrossrefPubMedGoogle Scholar
  • 4 Twomey JD, Zhang B. Cancer immunotherapy update: FDA-approved checkpoint inhibitors and companion diagnostics. AAPS J 2021; 23 (02) 39 DOI: 10.1208/s12248-021-00574-0.
    CrossrefPubMedGoogle Scholar
  • 5 Tsao MS, Kerr KM, Kockx M. et al. PD-L1 immunohistochemistry comparability study in real-life clinical samples: results of blueprint phase 2 project. J Thorac Oncol 2018; 13 (09) 1302-1311
    CrossrefPubMedGoogle Scholar